ATE449619T1 - Methode zur verminderung der immunerkennung - Google Patents

Methode zur verminderung der immunerkennung

Info

Publication number: ATE449619T1
Authority: AT; Austria
Prior art keywords: arginine; nitric oxide; inhibitor; immune detection; gelatin
Prior art date: 1998-07-10

Application number

AT99933792T

Other languages

English (en)

Inventor

Anton-Lewis Usala

Richard Klann

Original Assignee

Encelle Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

1999-07-09

Publication date

2009-12-15

1999-07-01 Priority claimed from US09/346,212 external-priority patent/US6352707B1/en

1999-07-09 Application filed by Encelle Inc filed Critical Encelle Inc

2009-12-15 Application granted granted Critical

2009-12-15 Publication of ATE449619T1 publication Critical patent/ATE449619T1/de

Links

238000000034 method Methods 0.000 title abstract 3
238000001514 detection method Methods 0.000 title 1
108010010803 Gelatin Proteins 0.000 abstract 2
229940123134 Nitric oxide inhibitor Drugs 0.000 abstract 2
229920000159 gelatin Polymers 0.000 abstract 2
239000008273 gelatin Substances 0.000 abstract 2
235000019322 gelatine Nutrition 0.000 abstract 2
235000011852 gelatine desserts Nutrition 0.000 abstract 2
239000011159 matrix material Substances 0.000 abstract 2
BUVCJVSDXCCEOY-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(ethylamino)pentanoic acid Chemical compound CCN[C@H](C(O)=O)CCCNC(N)=N BUVCJVSDXCCEOY-LURJTMIESA-N 0.000 abstract 1
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
229920002307 Dextran Polymers 0.000 abstract 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 abstract 1
MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229940088382 Nitric oxide scavenger Drugs 0.000 abstract 1
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
229960002433 cysteine Drugs 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
229960003067 cystine Drugs 0.000 abstract 1
229960002086 dextran Drugs 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/022—Artificial gland structures using bioreactors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/114—Nitric oxide, i.e. NO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Transplantation (AREA)
Oral & Maxillofacial Surgery (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Materials Engineering (AREA)
Botany (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dispersion Chemistry (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gynecology & Obstetrics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Materials For Medical Uses (AREA)
Prostheses (AREA)

AT99933792T 1998-07-10 1999-07-09 Methode zur verminderung der immunerkennung ATE449619T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/113,437 US6231881B1 (en)	1992-02-24	1998-07-10	Medium and matrix for long-term proliferation of cells
US09/346,212 US6352707B1 (en)	1992-02-24	1999-07-01	Transplant encapsulation in a hydrogel matrix to obscure immune recognition
PCT/US1999/015465 WO2000002600A1 (en)	1998-07-10	1999-07-09	Method of obscuring immune recognition

Publications (1)

Publication Number	Publication Date
ATE449619T1 true ATE449619T1 (de)	2009-12-15

Family

ID=22349408

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99935483T ATE326243T1 (de)	1998-07-10	1999-07-09	Methoden zur verbesserung der vaskularisierung und förderung der wundheilung
AT99933792T ATE449619T1 (de)	1998-07-10	1999-07-09	Methode zur verminderung der immunerkennung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT99935483T ATE326243T1 (de)	1998-07-10	1999-07-09	Methoden zur verbesserung der vaskularisierung und förderung der wundheilung

Country Status (9)

Country	Link
US (5)	US6231881B1 (de)
EP (1)	EP1098959A2 (de)
JP (1)	JP2002520013A (de)
AT (2)	ATE326243T1 (de)
AU (1)	AU758833B2 (de)
CA (1)	CA2332701C (de)
DE (1)	DE69941707D1 (de)
ES (1)	ES2337320T3 (de)
WO (1)	WO2000002999A2 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6703017B1 (en)	1994-04-28	2004-03-09	Ixion Biotechnology, Inc.	Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US7070607B2 (en) *	1998-01-27	2006-07-04	The Regents Of The University Of California	Bioabsorbable polymeric implants and a method of using the same to create occlusions
US6905707B2 (en) *	1998-05-28	2005-06-14	Medical Research Institute	Controlled release arginine alpha ketoglutarate
EP1025861A1 (de) *	1999-02-04	2000-08-09	Roche Diagnostics GmbH	Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
ES2346400T3 (es) *	1999-04-30	2010-10-15	Neurotrophincell Pty Ltd	Xenotransplante para la terapia del snc.
US20090047325A1 (en) *	1999-04-30	2009-02-19	Neurotrophincell Pty. Limited	Xenotransplant for cns therapy
US20050265977A1 (en) *	1999-04-30	2005-12-01	Elliott Robert B	Xenotransplant for CNS therapy
WO2001019962A2 (en) *	1999-09-15	2001-03-22	Encelle, Inc.	Method of preserving tissue viability during mechanical separation process
AU780366B2 (en) *	2000-01-20	2005-03-17	Diatranz Otsuka Limited	Preparation and xenotransplantation of porcine islets
CA2410965C (en) *	2000-05-31	2010-09-14	Encelle, Inc.	Method of stimulating hair growth
EP1333846B1 (de) *	2000-10-17	2012-04-18	Diabcell Pty Limited	Zubereitung und xenotransplantation von langerhans-inseln von schweinen
US20020188170A1 (en) *	2001-04-27	2002-12-12	Santamore William P.	Prevention of myocardial infarction induced ventricular expansion and remodeling
WO2002092783A2 (en) *	2001-05-15	2002-11-21	Children's Medical Center Corporation	Methods and apparatus for application of micro-mechanical forces to tissues
US20040097401A1 (en) *	2002-11-14	2004-05-20	Debatosh Datta	Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions
US6702744B2 (en)	2001-06-20	2004-03-09	Advanced Cardiovascular Systems, Inc.	Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
AU2002318159A1 (en)	2001-06-29	2003-03-03	The Regents Of The University Of California	Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
US6790455B2 (en) *	2001-09-14	2004-09-14	The Research Foundation At State University Of New York	Cell delivery system comprising a fibrous matrix and cells
US8608661B1 (en)	2001-11-30	2013-12-17	Advanced Cardiovascular Systems, Inc.	Method for intravascular delivery of a treatment agent beyond a blood vessel wall
JP4489437B2 (ja)	2002-02-21	2010-06-23	エンセル，インコーポレイテッド	表面コーティングとしての固定化生物活性ヒドロゲルマトリックス
US20080086792A1 (en)	2006-10-13	2008-04-17	Thomas Charles Kuracina	Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
US20030228287A1 (en) *	2002-06-07	2003-12-11	Regents Of The University Of California	Maintenance of islet cells
US7361368B2 (en)	2002-06-28	2008-04-22	Advanced Cardiovascular Systems, Inc.	Device and method for combining a treatment agent and a gel
US20060110826A1 (en) *	2002-07-30	2006-05-25	Massachusetts Institute Of Technology	Methods for perfusion and plating of primary hepatocytes and a medium therefore
EP1391284A1 (de) *	2002-08-23	2004-02-25	Kasai Kogyo Co., Ltd.	Schichtverbund und dessen Herstellungsverfahren
US8821473B2 (en)	2003-04-15	2014-09-02	Abbott Cardiovascular Systems Inc.	Methods and compositions to treat myocardial conditions
US8038991B1 (en)	2003-04-15	2011-10-18	Abbott Cardiovascular Systems Inc.	High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8383158B2 (en)	2003-04-15	2013-02-26	Abbott Cardiovascular Systems Inc.	Methods and compositions to treat myocardial conditions
WO2005042048A2 (en) *	2003-10-22	2005-05-12	Encelle, Inc.	Bioactive hydrogel compositions for regenerating connective tissue
US20050245905A1 (en) *	2004-04-30	2005-11-03	Schmidt Steven P	Local drug-delivery system
CN1993460A (zh) *	2004-07-12	2007-07-04	索林集团意大利有限公司	用于培养人细胞的装置和方法
US7784697B2 (en)	2004-12-23	2010-08-31	University Of Washington	Methods of driving a scanning beam device to achieve high frame rates
US20060178696A1 (en) *	2005-02-04	2006-08-10	Porter Stephen C	Macroporous materials for use in aneurysms
US9427496B2 (en)	2005-02-18	2016-08-30	Drexel University	Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering
US20080125745A1 (en)	2005-04-19	2008-05-29	Shubhayu Basu	Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en)	2005-04-19	2014-09-09	Advanced Cardiovascular Systems, Inc.	Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en)	2005-04-19	2017-01-10	Abbott Cardiovascular Systems Inc.	Methods and compositions for treating post-cardial infarction damage
US8303972B2 (en)	2005-04-19	2012-11-06	Advanced Cardiovascular Systems, Inc.	Hydrogel bioscaffoldings and biomedical device coatings
US8187621B2 (en)	2005-04-19	2012-05-29	Advanced Cardiovascular Systems, Inc.	Methods and compositions for treating post-myocardial infarction damage
US9942511B2 (en)	2005-10-31	2018-04-10	Invention Science Fund I, Llc	Preservation/degradation of video/audio aspects of a data stream
NZ540597A (en) *	2005-06-08	2007-02-23	Neurotrophincell Pty Ltd	A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
EP1922052B1 (de) *	2005-08-08	2010-11-03	Angstrom Medica, Inc.	Zementprodukte sowie verfahren zu deren herstellung und verwendung
DE102005054937A1 (de) *	2005-11-17	2007-05-24	Gelita Ag	Angiogenese förderndes Substrat
JP2009524408A (ja)	2005-11-30	2009-07-02	マサチューセッツ・インスティテュート・オブ・テクノロジー	病原体を検出する細胞保存系
US20070231901A1 (en) *	2005-12-02	2007-10-04	Shuichi Takayama	Microfluidic cell culture media
US20070149440A1 (en) *	2005-12-28	2007-06-28	Essential Skincare, Llc	Transferrin and transferrin-based compositions for diabetes treatment
US8999933B2 (en) *	2006-01-18	2015-04-07	Biolitec Pharma Marketing Ltd	Photodynamic cosmetic procedure and healing method
US20090004159A1 (en) *	2006-01-24	2009-01-01	The Board Of Trustees Of The University Of Illinoi	Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) *	2006-01-24	2007-08-23	Northfield Laboratories Inc.	Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US7732190B2 (en)	2006-07-31	2010-06-08	Advanced Cardiovascular Systems, Inc.	Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en)	2006-08-21	2016-01-26	Abbott Cardiovascular Systems Inc.	Pro-healing agent formulation compositions, methods and treatments
US20080069855A1 (en) *	2006-08-21	2008-03-20	Bonutti Peter M	Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
AU2007297776A1 (en) *	2006-09-21	2008-03-27	Tissue Genesis, Inc.	Cell delivery matrices
US8741326B2 (en)	2006-11-17	2014-06-03	Abbott Cardiovascular Systems Inc.	Modified two-component gelation systems, methods of use and methods of manufacture
US9005672B2 (en)	2006-11-17	2015-04-14	Abbott Cardiovascular Systems Inc.	Methods of modifying myocardial infarction expansion
US8192760B2 (en)	2006-12-04	2012-06-05	Abbott Cardiovascular Systems Inc.	Methods and compositions for treating tissue using silk proteins
CN101677862B (zh)	2007-02-06	2012-04-18	先锋外科技术公司	椎间植入装置及其插入方法
DK2155248T3 (en)	2007-04-12	2015-09-14	Brigham & Womens Hospital	Targeting abcb5 for cancer therapy
EP2152196A1 (de)	2007-05-01	2010-02-17	The Brigham and Women's Hospital, Inc.	Wundheilungsvorrichtung
DE102007024239A1 (de) *	2007-05-16	2008-11-20	Gelita Ag	Angiogenese förderndes Substrat
EP2192886B1 (de)	2007-08-28	2017-12-20	Pioneer Surgical Technology, Inc.	Zementprodukte sowie verfahren zu deren herstellung und verwendung
US20120301444A1 (en) *	2007-09-27	2012-11-29	Clarke Diana L	Amnion-derived cell compositions, methods of making and uses thereof
US20090090214A1 (en) *	2007-10-04	2009-04-09	Chung Yuan Christian University	Method for forming nano-scale metal particles
US20090130756A1 (en) *	2007-11-20	2009-05-21	Pioneer Surgical Orthobiologics,Inc.	Cryopreservation of cells using cross-linked bioactive hydrogel matrix particles
EP2273952B1 (de)	2008-04-02	2018-02-21	Pioneer Surgical Technology, Inc.	Bandscheibenimplantatvorrichtungen zur unterstützung der wirbel und vorrichtungen zu ihrer einführung
WO2009137074A1 (en) *	2008-05-06	2009-11-12	Indigene Pharmaceuticals, Inc.	Compositions and methods for treating diabetic ulcers
PL2470228T3 (pl)	2009-08-28	2018-03-30	Sernova Corporation	Sposoby i urządzenia do przeszczepiania komórek
CN106913902A (zh)	2009-11-09	2017-07-04	聚光灯技术合伙有限责任公司	多糖基水凝胶
CN102695501A (zh)	2009-11-09	2012-09-26	聚光灯技术合伙有限责任公司	碎裂水凝胶
AU2011247984B2 (en) *	2010-05-07	2015-04-30	University Of North Carolina At Chapel Hill	Method of engrafting cells from solid tissues
WO2012048276A2 (en)	2010-10-08	2012-04-12	Caridianbct, Inc.	Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP5808631B2 (ja) *	2011-09-29	2015-11-10	富士フイルム株式会社	血管新生用足場、及び再生医療用の血管の製造方法
US9132021B2 (en)	2011-10-07	2015-09-15	Pioneer Surgical Technology, Inc.	Intervertebral implant
EP2776052B1 (de)	2011-11-02	2017-06-14	Halscion, Inc.	Methoden und zusammensetzungen zur wundbehandlung
CA2860227C (en)	2011-12-23	2020-03-24	Pioneer Surgical Technology	Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
US20150072966A1 (en)	2012-03-01	2015-03-12	3M Innovative Properties Company	Method of promoting wound healing
US9101707B2 (en)	2012-04-27	2015-08-11	Gregory Zeltser	Implantable bioartificial perfusion system
WO2014089472A1 (en) *	2012-12-07	2014-06-12	Kansas State University Research Foundation	Peptide-albumin hydrogel properties and its applications
AU2014219026B2 (en)	2013-02-19	2018-11-29	Children's Medical Center Corporation	ABCB5(+) stem cells for treating ocular disease
EP4008369A1 (de)	2013-05-10	2022-06-08	Children's Medical Center Corporation	Wundheilung und gewebeaufbau
US9616046B2 (en)	2013-06-28	2017-04-11	Japan Bio Products Co., Ltd.	Hepatocyte-proliferating agent
WO2015073913A1 (en)	2013-11-16	2015-05-21	Terumo Bct, Inc.	Expanding cells in a bioreactor
WO2015148704A1 (en)	2014-03-25	2015-10-01	Terumo Bct, Inc.	Passive replacement of media
EP3198006B1 (de)	2014-09-26	2021-03-24	Terumo BCT, Inc.	Geplante fütterung
EP3247716A4 (de)	2015-01-20	2018-10-17	Miragen Therapeutics, Inc.	Mir-92-inhibitoren und verwendungen davon
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
WO2017004592A1 (en)	2015-07-02	2017-01-05	Terumo Bct, Inc.	Cell growth with mechanical stimuli
US11965175B2 (en)	2016-05-25	2024-04-23	Terumo Bct, Inc.	Cell expansion
US11685883B2 (en)	2016-06-07	2023-06-27	Terumo Bct, Inc.	Methods and systems for coating a cell growth surface
US11104874B2 (en)	2016-06-07	2021-08-31	Terumo Bct, Inc.	Coating a bioreactor
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
US10815456B2 (en)	2016-10-04	2020-10-27	Transwell Biotech Co., Ltd.	Composition, kit and method for cryopreserving cells
US12234441B2 (en)	2017-03-31	2025-02-25	Terumo Bct, Inc.	Cell expansion
CN117247899A (zh)	2017-03-31	2023-12-19	泰尔茂比司特公司	细胞扩增
US11624046B2 (en)	2017-03-31	2023-04-11	Terumo Bct, Inc.	Cell expansion
WO2019021143A1 (en) *	2017-07-22	2019-01-31	Rangasamy Naidu Educational Trust	HYDROGEL BASED ON L-HISTIDINE MOLECULES
JP7521152B2 (ja)	2017-09-08	2024-07-24	エクスタントメディカルホールディングス，インコーポレイテッド．	椎間インプラント、器具、及び方法
USD907771S1 (en)	2017-10-09	2021-01-12	Pioneer Surgical Technology, Inc.	Intervertebral implant
EP4314244B1 (de)	2021-03-23	2025-07-23	Terumo BCT, Inc.	Zellerfassung und -erweiterung
US12209689B2 (en)	2022-02-28	2025-01-28	Terumo Kabushiki Kaisha	Multiple-tube pinch valve assembly
USD1099116S1 (en)	2022-09-01	2025-10-21	Terumo Bct, Inc.	Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4477567A (en)	1977-12-01	1984-10-16	Connaught Laboratories Limited	Continuous bovine beta cell line
US4198479A (en)	1979-03-30	1980-04-15	Merck & Co., Inc.	Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en)	1982-04-30	1985-06-04	The Regents Of The University Of California	Growing of long-term biological tissue correction structures in vivo
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US5132223A (en)	1983-11-10	1992-07-21	Thomas Jefferson University	Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US4868121A (en)	1985-02-07	1989-09-19	Mcdonnell Douglas Corporation	Islet isolation process
US4978616A (en)	1985-02-28	1990-12-18	Verax Corporation	Fluidized cell cultivation process
NO166836C (no) *	1985-03-14	1991-09-11	Univ California	Fremgangsmaate for behandling av et organtransplantat.
US4863856A (en)	1985-04-04	1989-09-05	Verax Corporation	Weighted collagen microsponge for immobilizing bioactive materials
US4997753A (en)	1985-04-04	1991-03-05	Verax Corporation	Weighted collagen microsponge for immobilizing bioactive material
US5100783A (en)	1985-05-10	1992-03-31	Verax Corporation	Weighted microsponge for immobilizing bioactive material
US4902295A (en)	1985-08-26	1990-02-20	Hana Biologics, Inc.	Transplantable artificial tissue
EP0213908A3 (de)	1985-08-26	1989-03-22	Hana Biologics, Inc.	Transplantierbares Kunstgewebe und Verfahren
GB8604497D0 (en)	1986-02-24	1986-04-03	Connaught Lab	Separation of islets of langerhans
FR2600076A1 (fr)	1986-06-12	1987-12-18	Fond Ctre Nal Transfusion	Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
US5079160A (en)	1987-06-08	1992-01-07	Lacy Paul E	Method to isolate clusters of cell subtypes from organs
US5457093A (en) *	1987-09-18	1995-10-10	Ethicon, Inc.	Gel formulations containing growth factors
EP0403650B1 (de) *	1988-03-09	1994-05-25	Terumo Kabushiki Kaisha	Für zellen eindringbares medizinisches material und kunsthaut
US4950483A (en)	1988-06-30	1990-08-21	Collagen Corporation	Collagen wound healing matrices and process for their production
EP0363125A3 (de)	1988-10-03	1990-08-16	Hana Biologics Inc.	Produkt, enthaltend vermehrungsfähige Bauchspeicheldrüsen-Endokrinezellen, und Verfahren
US4957902A (en) *	1988-12-20	1990-09-18	Board Of Regents, The University Of Texas System	Peptide inhibitors of wound contraction
US5196185A (en) *	1989-09-11	1993-03-23	Micro-Collagen Pharmaceutics, Ltd.	Collagen-based wound dressing and method for applying same
WO1991009119A1 (en)	1989-12-13	1991-06-27	Trancel Corporation	Improved alginate microcapsules, methods of making and using same
US5645591A (en)	1990-05-29	1997-07-08	Stryker Corporation	Synthetic bone matrix
US5336616A (en)	1990-09-12	1994-08-09	Lifecell Corporation	Method for processing and preserving collagen-based tissues for transplantation
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
US5192312A (en)	1991-03-05	1993-03-09	Colorado State University Research Foundation	Treated tissue for implantation and methods of treatment and use
ATE156344T1 (de)	1991-04-25	1997-08-15	Univ Brown Res Found	Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5605938A (en)	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0605428B9 (de)	1991-06-24	2003-01-02	hCell Technology, Inc.	In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
CA2071137A1 (en)	1991-07-10	1993-01-11	Clarence C. Lee	Composition and method for revitalizing scar tissue
US5116753A (en)	1991-07-30	1992-05-26	The Salk Institute For Biological Studies	Maintenance of pancreatic islets
US5591709A (en) *	1991-08-30	1997-01-07	Life Medical Sciences, Inc.	Compositions and methods for treating wounds
WO1994015589A1 (en)	1992-12-30	1994-07-21	Clover Consolidated, Limited	Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5830492A (en)	1992-02-24	1998-11-03	Encelle, Inc.	Bioartificial devices and cellular matrices therefor
US5834005A (en)	1992-02-24	1998-11-10	Encelle, Inc.	Bioartificial devices and cellular matrices therefor
JP3291297B2 (ja)	1992-02-24	2002-06-10	エンセル，インコーポレイテッド	生物人工内分泌装置
US5824331A (en)	1992-02-24	1998-10-20	Encelle, Inc.	Bioartificial devices and cellular matrices therefor
ATE204470T1 (de)	1992-05-29	2001-09-15	Vivorx Inc	Mikroverkapselung von zellen
WO1994003154A1 (en)	1992-07-29	1994-02-17	Washington University	Use of pouch for implantation of living cells
US5262055A (en)	1992-10-19	1993-11-16	The University Of Utah	Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (de)	1993-03-03	1997-03-20	Michael Sittinger	Verfahren zum Herstellen eines Implantates aus Zellkulturen
US5405772A (en)	1993-06-18	1995-04-11	Amgen Inc.	Medium for long-term proliferation and development of cells
JPH09510182A (ja)	1993-11-17	1997-10-14	エルディーエス・テクノロジーズ・インコーポレーテッド	カプセル封入されたドラッグデリバリー用透明液
DK1666585T3 (da)	1994-01-13	2009-01-12	Rogosin Inst	Makroindkapslede sekretoriske celler
US5512477A (en)	1994-04-21	1996-04-30	Genzyme Corporation	Serum-free medium supplement
US5716404A (en)	1994-12-16	1998-02-10	Massachusetts Institute Of Technology	Breast tissue engineering
US5840059A (en)	1995-06-07	1998-11-24	Cardiogenesis Corporation	Therapeutic and diagnostic agent delivery
WO1997002569A1 (en)	1995-07-03	1997-01-23	Autronic Plastics, Inc.	Package and storage unit for digital information storage media
US5681587A (en)	1995-10-06	1997-10-28	Desmos, Inc.	Growth of adult pancreatic islet cells
US5672361A (en)	1996-03-29	1997-09-30	Desmos, Inc.	Laminin 5 for growth of pancreatic islet cells
CA2179341A1 (en)	1996-04-12	1997-10-13	Gregory S. Korbutt	Methods for isolating, enriching and increasing the maturation of cells
WO1998004681A2 (en)	1996-07-25	1998-02-05	Genzyme Corporation	Chondrocyte media formulations and culture procedures
WO1998016629A1 (en)	1996-10-11	1998-04-23	Life Technologies, Inc.	Defined systems for epithelial cell culture and use thereof

1998
- 1998-07-10 US US09/113,437 patent/US6231881B1/en not_active Expired - Fee Related
1999
- 1999-06-22 US US09/337,959 patent/US6261587B1/en not_active Expired - Fee Related
- 1999-07-09 EP EP99933791A patent/EP1098959A2/de not_active Withdrawn
- 1999-07-09 ES ES99933792T patent/ES2337320T3/es not_active Expired - Lifetime
- 1999-07-09 WO PCT/US1999/015464 patent/WO2000002999A2/en not_active Ceased
- 1999-07-09 DE DE69941707T patent/DE69941707D1/de not_active Expired - Lifetime
- 1999-07-09 AU AU49772/99A patent/AU758833B2/en not_active Ceased
- 1999-07-09 AT AT99935483T patent/ATE326243T1/de not_active IP Right Cessation
- 1999-07-09 CA CA2332701A patent/CA2332701C/en not_active Expired - Fee Related
- 1999-07-09 JP JP2000559221A patent/JP2002520013A/ja active Pending
- 1999-07-09 AT AT99933792T patent/ATE449619T1/de not_active IP Right Cessation
2001
- 2001-01-11 US US09/758,676 patent/US6730315B2/en not_active Expired - Fee Related
- 2001-01-11 US US09/758,793 patent/US6315994B2/en not_active Expired - Fee Related
- 2001-01-19 US US09/766,330 patent/US6713079B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2337320T3 (es)	2010-04-22
CA2332701A1 (en)	2000-01-20
WO2000002999A3 (en)	2000-04-20
WO2000002999A2 (en)	2000-01-20
EP1098959A2 (de)	2001-05-16
AU758833B2 (en)	2003-04-03
ATE326243T1 (de)	2006-06-15
US6713079B2 (en)	2004-03-30
AU4977299A (en)	2000-02-01
US20010019841A1 (en)	2001-09-06
US6231881B1 (en)	2001-05-15
CA2332701C (en)	2010-04-20
US20010010826A1 (en)	2001-08-02
JP2002520013A (ja)	2002-07-09
US6261587B1 (en)	2001-07-17
DE69941707D1 (de)	2010-01-07
US20010007658A1 (en)	2001-07-12
US6730315B2 (en)	2004-05-04
US6315994B2 (en)	2001-11-13

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE449619T1 (de)	2009-12-15	Methode zur verminderung der immunerkennung
ATE321126T1 (de)	2006-04-15	Hydrogelmatrix für zellgewebelagerung
ATE543506T1 (de)	2012-02-15	Methode zur stabilisierung von proteinen
CA2410968A1 (en)	2001-12-06	Method of treating chronic ulcers
ATE367398T1 (de)	2007-08-15	Verfahren zur rückfaltung von proteinen mit freien cysteinresten
DE69834136D1 (de)	2006-05-18	Gefrierschutzprotein
EP1548107A4 (de)	2006-07-26	Chromoprotein und fluoroproteine
TR200400639T4 (tr)	2004-05-21	Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
BRPI0511005A (pt)	2007-11-20	peptìdeos oligoméricos e seu uso para o tratamento de infecções por hiv
TR200002101T2 (tr)	2001-01-22	Dondurulmuş gıda ürünü.
DE60227670D1 (de)	2008-08-28	Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges
RU2010142486A (ru)	2012-04-27	Частичный пептид лакритина
CA2337051A1 (en)	2000-01-20	Methods for increasing vascularization and promoting wound healing
PT1296675E (pt)	2004-11-30	Composicoes a base de aminoacidos apropriadas para o tratamento da insuficienciacardiaca
EP1271555A4 (de)	2005-06-08	Strahlungsschutzmaterialien und deren verwendung
JPS56103106A (en)	1981-08-18	Protective agent of hair for permanent wave
MY142040A (en)	2010-08-30	Nitrosophenols and c-nitrosoanilines as polymerization inhibitors
PE20040537A1 (es)	2004-11-04	Fitasas modificadas
Baba et al.	2005	Purification and characterization of kininogens from sheep plasma
CY1108340T1 (el)	2014-02-12	Συνδυασμος του edg5 πολυμορφισμου v286a με σακχαρωδη διαβητη τυπου ii και φλeβικη θρομβωση / πνευμονικη εμβολη και η χρηση αυτου
ATE510008T1 (de)	2011-06-15	Entzündungshemmende peptide
ATE348840T1 (de)	2007-01-15	Verfahren zur prävention einer durch gefrieren induzierten abnahme der aktivität eines proteins
ATE459332T1 (de)	2010-03-15	Kosmetisches oder therapeutisches kombinationspräparat mit theanin
ES2191410T3 (es)	2003-09-01	Procedimiento de conservacion de objetos plateados y aparato de depuracion para su realizacion.
DE60038368D1 (de)	2008-04-30	Enzymatisches behandlungsverfahren